5PSQ-142 Risk factors for hyponatraemia in elderly patients, beyond pharmacological adverse effects. (March 2019)

• Record Type: Journal Article
• Authors: Miralles-Albors, P; Ortonobes Roig, S; Puig Comas, G; Pérez Contel, A; Férnandez-Molina, S; Badia Cebada, L; Cabrera Pajaron, M; Navarro Sáez, MDC; Comet Monte, R; Villarino Marzo, MA; Gómez-Valent, M
• Is Part Of: European journal of hospital pharmacy. Volume 26(2019)Supplement 1
• Page Start: A267
• Page End: A267
• Publication Date: 2019-03
• Subjects: Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2019-eahpconf.575
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background: Hyponatraemia is the most frequent electrolyte disorder among elderly patients (9.4%–15.0% of prevalence). It is rarely attributed to pharmacological causes despite being one of the most common drug-induced electrolyte abnormalities. Although some studies have shown an increase in mortality, others have failed to confirm this association. Purpose: To estimate the prevalence of hyponatraemia in geriatric patients. To determine which chronic drugs or alternative risk factors are associated with hyponatraemia and whether hyponatraemia is related to re-admission or mortality. Material and methods: We included ≥80 years' old patients consecutively admitted from March to July 2018 in an Acute Geriatric Unit (81 beds) of a University Hospital. Data collected: age, sex, pre-admission Barthel and Pfeiffer tests, number and family of chronic drugs, laboratory test, comorbidities, length of stay (LOS), mortality, re-admission and mortality at 30 days post-discharge. Results: Conclusion: The studied population displays hyponatraemia prevalence slightly above those of published values (see table 1 ). Hyponatraemia is associated with the use of thiazides and other factors such as age (>90 years), functional capacity, renal function and diabetes mellitus. Instead, re-admission and mortality rates remain unaltered. References and/or acknowledgements: No conflict of interest.